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Abstract
Background: The present study investigated factors associated with therapeutic benefits after autologous bone
marrow cell (BMC) therapy in patients with “no-option” critical limb ischemia (CLI).
Methods and results: Sixty-two patients with advanced CLI (Rutherford category 5 or 6) not eligible for
revascularization were randomized to treatment with 40 ml of autologous BMCs (SmartPreP2) by local intramuscular
(n = 32) or intra-arterial (n = 30) application. The primary endpoint was limb salvage and wound healing at
12 months. Seven patients (11 %) died during the follow-up from reasons unrelated to stem cell therapy. The BMC
product of patients with limb salvage and wound healing (33/55) was characterized by a higher CD34+ cell count
(p = 0.001), as well as a higher number of total bone marrow mononuclear cells (BM-MNCs) (p = 0.032), than that
of nonresponders (22/55). Patients with limb salvage and wound healing were younger (p = 0.028), had lower
C-reactive protein levels (p = 0.038), and had higher transcutaneous oxygen pressure (tcpO2) (p = 0.003) before
cell application than nonresponders. All patients with major tissue loss at baseline (Rutherford 6 stage of CLI,
n = 5) showed progression of limb ischemia and required major limb amputation. In the multiple binary logistic
regression model, the number of applied CD34+ cells (p = 0.046) and baseline tcpO2 (p = 0.031) were independent
predictors of limb salvage and wound healing. The number of administrated BM-MNCs strongly correlated with
decreased peripheral leukocyte count after 6 months in surviving patients with limb salvage (p = 0.0008).
Conclusion: Patients who benefited from autologous BMC therapy for “no-option” CLI were treated with high
doses of CD34+ cells. The absolute number of applied BM-MNCs correlated with the improvement of inflammation. We
hypothesize that the therapeutic benefit of cell therapy for peripheral artery disease is the result of synergistic effects
mediated by a mixture of active cells with regenerative potential. Patients at the most advanced stage of CLI do not
appear to be suitable candidates for cell therapy.
Trial registration: The study was approved and registered by the ISRCTN registry. Trial registration: ISRCTN16096154.
Registered: 26 July 2016.
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Background
Cell therapy is emerging as an alternative strategy for
the treatment of patients with critical limb ischemia
(CLI) who are not eligible for endovascular or surgical
revascularization. Several preclinical and clinical studies
suggest that delivery of progenitor stem cells improves
blood circulation and tissue perfusion, preventing ampu-
tation via the induction of capillary or collateral growth
in a process called “therapeutic angiogenesis” [1]. Al-
though many cell types have been tested, most clinical
trials to date have relied on the use of adult autologous
bone marrow-derived mononuclear cells (BM-MNCs) or
cultured peripheral blood-derived mononuclear cells
[2–4]. Alternatively, mesenchymal stem cells (MSCs)
have gained therapeutic interest in interventions aimed
at tissue restoration because of their multipotent differ-
entiation capacity and their cytoprotective and imuno-
modulatory effects [5–8]. The aim of the present study
was to address factors associated with the therapeutic
benefits of cellular therapy in patients who are not




During the inclusion period of 30 months, 62 patients
(age 64 ± 11 years; male:female ratio 54:8) with advanced
CLI (Rutherford category 5 or 6) after failed or impos-
sible revascularization were randomized into two groups
and treated with 40 ml of bone marrow nucleated cells
via the local intramuscular (IM) route (n = 32) or via se-
lective intra-arterial (IA) infusion (n = 30), with equal
sex distribution and equal distribution of patients with
diabetes in both groups [9]. The etiology of arterial oblit-
eration was atherosclerosis in 56 patients and throm-
boangiitis obliterans (Buerger disease) in six patients.
Inclusion criteria
(1) Patients older than 18 years with ischemic skin le-
sions (ulcer or gangrene) with CLI Rutherford category
5 or 6 according to the Transatlantic Inter-Society Con-
sensus (TASC) classification (minor or major tissue loss)
[10], or major tissue loss, defined as necrosis or gan-
grene extending proximal to the metatarsal line or as
extensive deep heel gangrene; (2) CLI, defined by an
ankle-brachial index (ABI) ≤0.4 or ankle systolic pres-
sure <50 mmHg, or toe systolic pressure <30 mmHg,
and transcutaneous oxygen pressure (tcpO2) <30 mmHg;
(3) no option for endovascular or surgical revasculariza-
tion as determined by both vascular surgeon and inter-
ventionalist; and (4) failed revascularization, defined as
no change of clinical status with the best standard care
4 weeks after endovascular or surgical revascularization.
Exclusion criteria
(1) Life expectancy of <6 months; (2) evidence of malig-
nancy during the last 5 years; (3) critical coronary artery
disease or unstable angina pectoris; (4) end-stage kidney
disease and patients on dialysis; and (5) bone marrow
disease (e.g., myelodysplastic syndrome, severe anemia,
leucopenia, thrombocytopenia).
Bone marrow cell isolation and administration
Isolation of stem cells was performed under analgoseda-
tion with propofol. A total of 240 ml of bone marrow
from both posterior iliac crests was harvested. Bone mar-
row aspirates were processed with the SmartPreP2 Bone
Marrow Aspirate Concentrate System (Harvest, Plymouth,
MA, USA). This system uses gradient density centrifuga-
tion to provide 40 ml of bone marrow product enriched
in all blood elements within 15 minutes [11, 12]. Immedi-
ately after stem cell harvest and centrifugation, the bone
marrow cell (BMC) concentrate was administered either
by IM application (under analgosedation with propofol by
deep IM injections into the muscles of the affected limb
along the crural arteries, with approximately 1 ml for each
injection) or by IA infusion (injection of 40 ml of BMC
using a percutaneous femoral approach with a 4 F catheter
at the site of arterial occlusion of the affected limb, at a
rate of 800 ml/hour).
Preprocedure assessment and follow-up
All patients were examined before and at 90 days,
6 months, and 12 months after BMC delivery. Peripheral
blood tests such as blood count and basal serological
parameters including C-reactive protein (CRP) were
assessed. The total concentration of mononuclear cells
(BM-MNCs) and CD34+ cells in bone marrow concen-
trates was evaluated. Soluble forms of the cell adhesion
molecules, markers for vascular endothelial activation or
injury (sE-selectin, sP-selectin, sICAM-1, sICAM-3,
sPECAM-1), and vascular endothelial growth factor
(VEGF) levels were determined in a subgroup of 45 pa-
tients in peripheral blood samples using commercially
available enzyme immunoassay (ELISA) kits (Adhesion
6-plex and FlowCytomix™ Kits; eBioscience, Austria;
VEGF-A Platinum ELISA; Bender MedSystems GmbH,
Austria).
Measurement of the resting ABI was performed
according to validated standards [13]. The tcpO2 of the
affected limb was assessed using a TCM400 Mk2 moni-
tor (Radiometer Medical ApS, Copenhagen, Denmark).
The tcpO2 was measured at the forefoot in the supine
position with an electrode temperature of 44 °C. Wound
characteristics were documented by digital photography.
Wound healing was evaluated by two independent
physicians. Pain was assessed using a visual analog scale
graded from 0 to 10. Patients were discharged the day
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after the procedure on dual antiplatelet therapy (aspirin
and clopidogrel) and statin therapy. All patients received
conventional wound care during follow-up.
Endpoints
The primary endpoint was limb salvage and wound heal-
ing at 12 months of follow-up. Surviving patients with
limb salvage and wound healing were considered re-
sponders to BMC therapy. Patients requiring major limb
amputation or those with no signs of wound healing
were considered nonresponders. Secondary endpoints
were mortality, amputation-free survival (AFS), major
limb amputation, change in tcpO2, Rutherford category,
and pain scale after BMC transplantation.
Statistical analysis
Data analysis was performed using the statistical software
package SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Discrete
variables are presented as counts and percentages.
Continuous variables are presented as mean values ± SD.
Gaussian distributions of data were tested with the
Kolmogorov–Smirnov test. A paired t test was used to
compare values before and after BMC transplantation.
The difference in interval variables between two outcome
groups was investigated in univariate analysis by two-way,
independent-samples Student t test (for equal variances)
or Welch t test (for unequal variances). For categorical
variables, the chi-square test was performed. Subse-
quently, multiple binary logistic regression analysis was
used to study predictors of clinical benefit after BMC
application. For all analyses, p <0.05 was considered
statistically significant.
Results
The main clinical results are presented in Table 1. Dur-
ing the follow-up of 12 months, seven patients died
(11 %): three of them from heart failure, three from
myocardial infarction, and one as a result of pneumonia.
Surviving patients (55/62 patients) were characterized by
lower age (63 ± 10 vs 76 ± 9 years, p = 0.001). At the 12-
month follow-up, the primary endpoint of limb salvage
with wound healing was reached in 33 of 55 surviving
patients (60 %). In 16 patients, major limb amputation
was required because of CLI progression. In six patients
with limb salvage there were no signs of wound healing.
The overall AFS rate was 63 % (39/62 patients) after
12 months. There were no differences in the primary or
secondary endpoints between patients receiving IM
application and those receiving IA application.
Characteristics of patients with limb salvage and wound
healing
Table 2 presents the characteristics of patients with
limb salvage and wound healing after cell application
compared with patients with major limb amputation or
nonhealing ulcers. BMCs in patients with limb salvage
and wound healing were characterized by a higher
CD34+ cell count (20 ± 10 vs 34 ± 19 × 109, p = 0.001)
and a higher number of total nucleated cells (3.8 ± 1.2
vs 4.5 ± 1.4 × 109, p = 0.032). These patients had lower
CRP levels (48 ± 77 vs 11 ± 18 mg/ml, p = 0.038) and
higher tcpO2 at baseline (9 ± 8 vs 16 ± 10 mmHg, p =
0.005) than nonresponders. All patients with major
tissue loss at baseline (Rutherford 6 stage of CLI, n = 5)
showed progression of limb ischemia and required
major limb amputation. Binary logistic regression was
performed to ascertain the effects of age, tcpO2, CRP,
and CD34+ on the likelihood of limb salvage and
wound healing. The binary logistic regression model
was statistically significant (χ2(4) = 22.78, p < 0.0001).
The model explained 45.8 % (Nagelkerke R2) of the vari-
ance in treatment outcome and correctly classified 76.4 %
of cases. The number of applied CD34+ cells (p = 0.046,
Exp(B) = 1.070, 95 % confidence interval (CI) 1.001–1.143)
and baseline tcpO2 (p = 0.031, Exp(B) = 1.102, 95 % CI
1.009–1.204) emerged as independent predictors of limb
salvage and wound healing.
Amputation-free survival
Surviving patients with limb salvage at the 12-month
follow-up (39/62 patients) were characterized by lower
age (61 ± 10 vs 70 ± 10 years, p = 0.002), lower levels of
baseline CRP (11 ± 18 vs 50 ± 75 mg/l, p = 0.022), and
higher tcpO2 levels (16 ± 10 vs 10 ± 9 mmHg, p = 0.01),
and received higher doses of atorvastatin (19 ± 15 v.
12 ± 9 mg, p = 0.027), than nonsurviving patients or
those with major limb amputation at the 12-month
follow-up (23/62 patients). The BMC product of sur-
viving patients with limb salvage was characterized by
a higher CD34+ cell count (32 ± 18 × 106 vs 22 ± 11 ×
106, p = 0.022) in univariate analysis. The binary logis-
tic regression model investigating the effects of age,
tcpO2, CRP, and CD34
+ on AFS was statistically signifi-
cant (χ2(4) = 26.20, p < 0.0001). The model explained
47 % (Nagelkerke R2) of the variance in treatment out-
come and correctly classified 82.3 % of cases. Only age
(p = 0.021, Exp(B) = 0.92, 95 % CI 0.857–0.988) and
baseline tcpO2 (p = 0.029, Exp(B) = 1.095, 95 % CI
1.009–1.187) were independent predictors of AFS. The
Table 1 Main results: 12-month follow-up after bone marrow cell
application (n = 62)
Outcome
Mortality 7/62 (11 %)
Amputation-free survival 39/62 (63 %)
Limb salvage 39/55 (71 %)
Limb salvage + wound healing 33/55 (60 %)
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number of total bone marrow nucleated cells strongly cor-
related with a decrease of peripheral leukocyte count after
6 months (p = 0.0008, r = –0.51). A similar but weaker cor-
relation was observed between the absolute number of
CD34+ cells and the decrease of peripheral leukocyte
count after 6 months (p = 0.02, r = –0.38) (Fig. 1). Patients
with limb salvage showed a significant improvement in
tcpO2, pain scale, quality of life, wound healing, and
Rutherford category at 6 months, persisting up to
12 months (Table 3).
Table 4 presents the serum levels of adhesion mole-
cules and VEGF before cell application in the subgroup
of 45 patients. Serum levels of sE-selectin and sICAM-1
were higher in surviving patients with limb salvage at
Table 2 Characteristics of patients before bone marrow cell application
All patients
(n = 62)
Limb salvage and wound healing
(n = 33)
Major limb amputation or nonhealing ulcer
(n = 22)
p valuea
Age (years) 64 ± 11 60 ± 11 66 ± 9 0.03
Sex (females) 8 (13 %) 4 (12 %) 4 (18 %) 0.53
Mode of administration (IM) 32 (52 %) 18 (55 %) 11 (50 %) 0.74
Diabetes mellitus 41 (66 %) 21 (64 %) 15 (68 %) 0.73
Arterial hypertension 48 (77 %) 22 (67 %) 19 (86 %) 0.10
Hyperlipidemia 32 (52 %) 18 (55 %) 12 (55 %) 1.0
Obesity (BMI > 30) 12 (19 %) 8 (24 %) 3 (14 %) 0.34
Smoking 25 (40 %) 16 (48 %) 7 (32 %) 0.22
Soluble creatinine (μmol/l) 95 ± 47 90 ± 40 91 ± 20 0.91
CRP (mg/l) 25 ± 51 11 ± 18 48 ± 77 0.04
Leu (109/l) 9.1 ± 4.7 8.8 ± 5.2 9.4 ± 4.2 0.64
Rutherford category 6b 5.1 ± 0.3 0 (0 %) 5 (23 %) 0.02
ABI 0.8 ± 0.4 0.8 ± 0.3 0.7 ± 0.5 0.70
tcpO2 baseline (mmHg) 14 ± 10 16 ± 10 9 ± 8 0.005
Pain scale (0–10) 4.7 ± 2.4 4.1 ± 2.5 5.7 ± 1.5 0.004
Fibrinogen (g/l) 3.9 ± 0.9 3.7 ± 0.9 4.1 ± 0.9 0.10
Cholesterol (mmol/l) 4.3 ± 1.1 4.4 ± 1.1 4.3 ± 0.9 0.78
Atorvastatin (mg) 17 ± 13 18 ± 10 15 ± 17 0.40
BM-MNCs (109) 4.2 ± 1.4 4.5 ± 1.4 3.8 ± 1.2 0.03
CD34+ (106) 28 ± 16 34 ± 19 20 ± 10 0.001
Thromboangiitis obliterans 6 (10 %) 6 (18 %) 0 0.03
aPatients with limb salvage and wound healing versus patients with major limb amputation or nonhealing ulcer
bOnly patients with category 5 and 6 were included in the study
ABI ankle-brachial index, BMI body mass index, BM-MNC bone marrow mononuclear cell, CRP C-reactive protein, IM intramuscular, Leu leukocyte level in peripheral
blood, tcpO2 transcutaneous oxygen pressure
Fig. 1 Decrease in peripheral leukocyte count 6 months after cell delivery in relation to the number of applied mononuclear cells (a) and CD34+
cells (b). Patients with limb salvage (n = 39). BM-MNC bone marrow mononuclear cell, Δ Leu change in leukocyte counts
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the 12-month follow-up than in nonsurvivors or those
with major limb amputation (p < 0.05). Serum levels of
sE-selectin at baseline were inversely correlated with age
(r = –0.36, p = 0.02).
Safety outcomes
After bone marrow aspiration, no bleeding complica-
tions or decrease in blood count requiring substitution
therapy emerged. No infection, local swelling, or other
adverse effects associated with cell application were
observed after IM or IA application. Both IM and IA
procedures were well tolerated. There was no evidence
of newly diagnosed malignancy or other adverse events
possibly associated with cell application during the
follow-up period.
Discussion
The present study investigated factors predictive of the
effect of BMC on the progression of advanced CLI. The
main findings can be summarized as follows: the num-
ber of applied CD34+ cells was an independent predictor
of limb salvage and wound healing; the absolute number
of applied BM-MNCs correlated with a decrease in the
peripheral leukocyte count; and extremely advanced
limb malperfusion is associated with lack of therapeutic
benefit from BMC therapy.
Despite several studies documenting the positive
clinical outcomes of cell therapy in patients with CLI,
the role of such therapy remains controversial. This
could be due to differences between studies regarding
administration route, cell type, cell source, or cell dose.
The recent well-designed, randomized, double-blind,
placebo-controlled JUVENTAS study [14] with repeti-
tive IA infusion of autologous BM-MNC in patients
with “no-option” CLI did not confirm the reduction of
major limb amputation rates after cell application, and
a relation between the number of BMCs administered
and clinical improvement was not observed. In the
present study, however, the number of CD34+ cells in
the BMC concentrate was an independent predictor of
therapeutic benefit in terms of limb salvage and wound
healing after 12 months. Of note, we used higher con-
centrations of applied mononuclear cells, as well as of
CD34+ cells, than the JUVENTAS trial. The surface ex-
pression of CD34, CD133, and vascular endothelial
growth factor receptor-2 (VEGFR-2/KDR) identifies a
population of endothelial progenitor cells (EPCs) with
enhanced potency for neovascularization of ischemic
tissue [15–17]. The CD34+ cells restored the microcir-
culation and improved tissue perfusion in preclinical
models [18] as well as in clinical series [19]. In the
present study, the total number of nucleated stem cells
administered during the procedure strongly correlated
with a decrease in the peripheral leukocyte count at
the 6-month follow-up. In the PROVASA trial, patients
with healing ulcers after IA BM-MNC application had
received a greater number of total BM-MNCs, as well
as of CD34+ cells. Repeated BM-MNC administration
and a greater number of administered BM-MNCs were
independent predictors of complete ulcer healing [20].
Our observations were in agreement with the concept
that cell therapy for peripheral artery disease benefits
from the application of a mixture of active cells with
regenerative potential and secretory capacity acting in
a synergistic manner. These cells are characterized by
their monocytic or MSC phenotype, and act predomin-
antly through the release of angiogenic growth factors
[5, 17, 21, 22]. Flow cytometric analysis of standard
Table 3 Parameters of limb ischemia after BMC delivery in










5.0 ± 0 3.9 ± 1.3 3.1 ± 1.4 <0.001
tcpO2 (mmHg) 16 ± 10 30 ± 14 27 ± 14 <0.001
ABI 0.8 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 0.45
Pain scale
(0–10)
4.3 ± 2.4 1.6 ± 1.6 1.1 ± 1.6 <0.001
QoL (0–100) 56 ± 16 70 ± 11 73 ± 12 <0.001
Wound size
(cm2)
6.5 ± 5.9 3.3 ± 5.1 1.7 ± 2.5 <0.001
*Before BMC vs 12-month follow-up
ABI ankle-brachial index, BMC bone marrow cell, QoL quality of life, tcpO2
transcutaneous oxygen pressure
Table 4 Cell adhesion molecules VEGF concentrations before bone marrow cell application: subgroup analysis (n = 45)
All patients (n = 45) Surviving patients with limb salvage (n = 31) Death or major limb amputation (n = 14) p value
sICAM-1 (ng/ml) 688 ± 287 738 ± 311 569 ± 181 0.03
sICAM-3 (ng/ml) 127 ± 76 126 ± 64 129 ± 101 0.93
sE-selectin (ng/ml) 125 ± 53 137 ± 54 98 ± 41 0.01
sP-selectin (ng/ml) 804 ± 620 818 ± 696 771 ± 429 0.78
sPECAM-1 (ng/ml) 419 ± 151 391 ± 144 481 ± 152 0.07
VEGF (pg/ml) 168 ± 183 185 ± 187 130 ± 170 0.34
s soluble, ICAM intercellular adhesion molecule, VEGF vascular endothelial growth factor, PECAM platelet endothelial cell adhesion molecule, E-selectin endothelial–
leukocyte adhesion molecule, P-selectin platelets activating adhesion molecule
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MSC markers revealed significantly higher expression
of CD44 and CD90 in patients with “no-option” CLI
and good responses to cell therapy compared with
nonresponders [6]. This position is supported by the
finding that CD34+-stimulated neovascularization is
enhanced by coculture with CD34– cells, including
macrophages, monocytes, T cells, B cells, and megakar-
yocytes [23]. CD34– cells are the key regulators of EPC
development and differentiation from CD34+ cells
through cell-to-cell interactions and paracrine actions
[24].
MSCs, which are broadly accepted as a crucial regen-
erative component of BM-MNC concentrate, have been
shown to be effective for treating limb ischemia in
animal models and human patients [7, 8]. Application of
MSCs has been shown to improve wound healing
predominantly through paracrine interactions inducing
endogenous reparatory processes. Successful wound
healing requires cell migration, angiogenesis, granulation
tissue formation, re-epithelization, and extracellular
matrix remodeling. Angiogenic factors and cytokines se-
creted by MSCs promote angiogenesis, decrease wound
inflammation by their immunomodulatory properties,
and enhance regeneration of skin structures. MSCs
have been shown to inhibit the expression of matrix
metalloproteinase-1, which suggests that MSCs sup-
press degradation of collagenous matrix and contribute
to fibroblast regeneration [4, 7, 8]. In addition, it has
been recognized that MSCs released rich secretome
together with extracellular exosomes that might be
responsible for transfer of regulatory gene products
needed for reparatory process induction [25].
The present data indicate that age is an independent
predictor of AFS. Serum levels of sE-selectin, a marker
of endothelial activation [26], were inversely correlated
with age. Surviving patients with limb salvage had higher
concentrations of both sE-selectin and sICAM-1 than
patients with no AFS. Aging affects the number, func-
tion, and composition of adult stem cells [27, 28]. Early
EPCs (defined as CD34+/KDR+ or CD133+/KDR+) isolated
from the peripheral blood of older individuals (average
age 61 years) were significantly impaired in terms of pro-
liferation, migration, and survival, compared with those
obtained from healthy young subjects (average age
25 years), with no differences in the number of EPCs
between the two groups [29]. In addition, an age-related
decline in the expression of proangiogenic factors,
including growth factors, cytokines, and hormones, is
likely to contribute to impaired EPC generation,
mobilization, migration, and survival [30]. Aging and
aging-related disorders also significantly impair the
survival and differentiation potential of BM-MSCs, thus
limiting their therapeutic efficacy. Functional impairment
of cells in polymorbid patients could be overcome by
cell modification (enhancement of cell potency before
administration—ex-vivo stimulation, genetic manipula-
tion) or by modification of the recipient environment,
and hence improvement of long-term cell retention, en-
graftment, and survival after transplantation. There is
also emerging interest in the identification of alterna-
tive cell sources for MSCs. Induced pluripotent stem
cells (iPSCs) and allogeneic MSCs may provide an alter-
native source of functional cells. Patient-specific iPSC-
MSCs and allogeneic MSCs from healthy donors can be
prepared as an “off-the-shelf” product for the treatment
of tissue ischemia [4, 31, 32]. Both fundamental re-
search as well as large randomized trials are needed to
further consolidate the evidence.
Finally, the present data also underscore the import-
ance of local ischemia and inflammation in the effects of
BMC therapy. The tcpO2, a routinely used parameter of
limb perfusion, was an independent predictor of limb
salvage and wound healing. In addition, we showed an
association between Rutherford stage 6 limb ischemia
and a negative therapeutic outcome of cell delivery. This
is consistent with the results of the PROVASA trial,
where patients with Rutherford class 6 CLI at baseline
did not respond to cell therapy [20]. Similarly, Gupta et al.
[33] showed that patients with impending amputation did
not derive any benefit from BM-MSC administration.
Thus, advanced local inflammation of ischemic tissues
likely generates a hostile environment for delivered stem
cells. Clinical studies should consider the timing of stem
cell therapy with regard to the deleterious inflammatory
setting.
Limitations
The main limitation of the study was the lack of a
control group of CLI patients who did not receive BMC
application. The absence of a control group does not
exclude the possibility of spontaneous healing in some
patients. Likewise, a relatively small number of patients
in the nonresponder group could cloud the predictive
power of the parameters associated with the benefits of
stem cell therapy. Accordingly, the current findings pro-
vide a mechanistic understanding and are hypothesis gen-
erating for future larger and placebo-controlled trials.
Conclusions
Cell therapy holds great promise for the effective treat-
ment of patients with “no-option” CLI and shows a
favorable safety profile. A higher concentration of BM-
MNCs, especially of CD34+ cells, was associated with
the clinical benefit of cell therapy. Conversely, the most
advance stage of limb ischemia and pending major limb
amputation were associated with a negative clinical
response. The outcome of cell therapy is determined by
the synergistic effect of various mechanisms mediated
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by a mixture of active cells, and of trophic factors and
cytokines acting in response to ischemia and inflamma-
tion in a coordinated fashion. These findings should be
considered in the design of larger studies addressing
the benefits of cell therapy in a high-risk population of
patients with CLI.
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